ANAVEX®1-41

About Anavex Life Sciences

Anavex Life Sciences leverages its SIGMACEPTOR™ Discovery Platform to develop precision medicine therapeutics for central nervous system (CNS) diseases. The company's lead asset, ANAVEX®2-73, has demonstrated promising clinical data in Alzheimer's disease and Rett syndrome, with multiple Phase 2/3 trials underway. Anavex's strategy focuses on targeting the sigma-1 receptor to restore cellular homeostasis and potentially modify disease progression. The company is publicly traded and advancing a pipeline of small molecules for conditions with significant unmet medical need.

Therapeutic Areas

Other Neurodegenerative Diseases Drugs